1. A comparison between accelerated hypofractionation and stereotactic ablative radiotherapy (SABR) for early-stage non-small cell lung cancer (NSCLC): results of a propensity score-matched analysis A Chiang 1, I Thibault 1, A Warner 2, G Rodrigues 2, D Palma 2, H Soliman 2, S Jain 1, I Poon 1, P Cheung 1 1 Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada 2 London Regional Cancer Program, London, Ontario, Canada

2. Baseline Characteristics CharacteristicAH (n=57)SABR (n=57)p Age (yrs)Median (range)75 (59-90)74 (54-93) 0.749 GenderMale51%49% 0.851 Female49%51% Performance033%35%0.262 165%56% 22%9% HistologyAdeno39%49%0.707 Squamous cell39%32% Large cell3% NOS19%16% T-category163%65%1.00 226%28% 37%5% 44%2% Diameter (cm)Median (range)2.5 (1-7.5)2.9 (1.1-5.8)0.964 StagingPET/CNS0%63% < 0.001 PET7%11% CNS25%16% None68%10% Follow-up (mos)Median (range)36 (3-109)32 (0.3-63)0.026

3. OutcomesOutcomes Overall Survival HR (95% CI): 2.33 (1.28, 4.23), p = 0.006 Local Control HR (95% CI): 5.56 (1.53, 20.21), p = 0.009

4. Distant Control HR (95% CI): 0.64 (0.30, 1.37), p = 0.249 Regional Control HR (95% CI): 3.96 (1.06, 14.86), p = 0.041 Freedom From Progression HR (95% CI): 1.30 (0.74, 2.30), p = 0.366

5. Multivariate Analysis OSHR (95% CI)p Performance1 vs. 0 1.94 (0.98, 3.84)0.058 2/3 vs. 010.86 (2.49, 47.40.002 *0.005 DiameterPer 1 cm increase1.41 (1.15, 1.72)<0.001 StagePET vs. Both 11.97 (2.6, 55.12)0.001 CNS vs. Both6.67 (1.87, 23.870.004 None vs. Both7.02 (1.88, 26.520.004 *0.011 LCHR (95% CI)p CohortAH vs. SABR 5.56 (1.53, 20.23)0.009 * denotes overall effect